Ventracor’s heart gives out
Thursday, 19 March, 2009
Ventracor is the first small cap biotech to fall victim to the venture capital drought, placing itself into voluntary administration today after failing to secure money to keep it a going concern.
Ventracor has been on the critical list for some time, with a product safety recall issued in February, just after calling a halt to trading. It voluntarily suspended from quotation on February 10.
Despite actual revenue from sales and achieving a key milestone in completing patient recruitment for its bridge-to-transplant clinical trial in the US, the company said in a statement today it was unable to raise enough capital or find a buyer. It said it preferred that an administrator be appointed now before the company became insolvent.
The writing was on the wall for the company for some time, with major staff turnover issues affecting confidence in the last two years. The company still hopes that its VentrAssist left ventricular assist device will be successfully commercialised at some stage.
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
